SEC Form 4 · accession 0001209191-19-013142
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matt Davidson
10% Owner
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 21, 2019 | S | 3,180 | $11.05 | D | 2,936,658 | D | |
| Common StockF3 | Feb 22, 2019 | S | 4,840 | $10.90 | D | 2,931,818 | D | |
| Common StockF4 | Feb 25, 2019 | S | 5,051 | $11.20 | D | 2,926,767 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
- F2The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.79 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.745 to $11.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.93 to $11.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.